October 28, 2016 8:11 PM ET

Life Sciences Tools and Services

Company Overview of Duke Clinical Research Institute

Company Overview

Duke Clinical Research Institute operates as an academic research organization in the United States and internationally. The company focuses on conducting clinical trials, managing patient registries, and performing landmark outcomes research. It offers services in the areas of advanced biomarkers, biostatistics, cardiovascular imaging, clinical events classification and review, clinical hotline or helpline, data management, discovery genomics, medical communications, project leadership, regulatory services and medical writing, safety surveillance, site management and clinical monitoring, site start-up, clinical monitoring, comparative effectiveness and outcomes studies, education/training, ...

2400 Pratt Street

North Pavilion

Durham, NC 27705

United States

Founded in 1969





Key Executives for Duke Clinical Research Institute

Chief Financial Officer
Chief of Division of Pediatric Cardiology and Director of Pediatrics Research
Managing Director of CCGE Research Operations
Associate Dean of Clinical & Translational Science and Director of Duke Center for Community & Population Health Improvement
Compensation as of Fiscal Year 2016.

Duke Clinical Research Institute Key Developments

Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute Expand Collaboration to Create Patient Registry for Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the registry of newly diagnosed IPF patients. One element of the IPF-PRO Registry is a bio-repository that stores blood samples that provide patient genetic material that may help to better understand the relationship of various biomarkers to patient outcomes. The Registry expansion will substantially increase the size of the bio-repository, creating additional opportunities for future translational research and the identification of novel biomarkers that may be predictive of disease outcomes or individual patient treatment responses.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Duke Clinical Research Institute, please visit www.dcri.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.